New Home2026-05-21T14:39:16+10:00

Transform Your Response

Transform Your Response

Patient-Led. Built From Lived Experience.

Learn to keep options open.

Keep options open

Where Patients Lose

The Patient Survival System

Biliary 101

Why This Foundation Exists

I am a late-stage 4 cholangiocarcinoma survivor and co-founder of Cholangiocarcinoma Foundation Australia alongside my wife, Claire.

What most patients need in that moment is not reassurance alone.

They need orientation.
What matters now.
What comes next.

That is why this Foundation exists.

Everything we build is designed around one goal:

Improving today’s patient survival – today.

View my bio

Just yesterday, I was a person. Today, I am a patient.
I must become the best patient I can be, so that I can become that person again.

Steve

Our People Our Community Our Culture

1505, 2026

NRG1 Fusion Cholangiocarcinoma

By |

Most patients miss pathways like this, not because they don’t qualify, but because rare fusion signals are never fully investigated in time. NRG1 Fusion Cholangiocarcinoma is now linked to a newly FDA-approved targeted therapy called BIZENGRI for patients carrying this rare fusion pathway.

Testimonials

Go to Top